Biomarkers are one of the primary medical signs to facilitate the early detection of Alzheimer's disease. The small beta-amyloid (Aβ) peptide is an important indicator for the disease. However, current methods to detect Aβ pathology are either invasive (lumbar puncture) or quite costly and not widely available (amyloid PET). Thus a less invasive and cheaper approach is demanded. MRI which has been used widely in preclinical AD has recently shown the capability to predict brain Aβ positivity. This motivates us to develop a method, SDF sparse convolution, taking MRI to predict Aβ positivity. We obtain subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and use our method to discriminate Aβ positivity. Theoretically, we provide analysis towards the understanding of what the network has learned. Empirically, it shows strong performance on par or even better than state of the art.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669623PMC
http://dx.doi.org/10.1109/EMBC46164.2021.9630850DOI Listing

Publication Analysis

Top Keywords

aβ positivity
12
alzheimer's disease
8
5
deep learning
4
learning sdf
4
sdf classifying
4
classifying brain
4
brain biomarkers
4
biomarkers biomarkers
4
biomarkers primary
4

Similar Publications

ClpB is a member of the protein-disaggregating chaperone machinery belonging to the AAA+ superfamily. This paper describes a new clpB gene from the halophilic methanoarchaeon Methanohalophilus portucalensis, which has not been reported previously in Archaea. The partial sequence of clpB was identified from the investigation of the salt-stress response of Meh.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!